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methodological quality. We analyze the cost per LYG results in relation with a commonly-accepted 
Spanish cost effectiveness threshold and the possible relation with the cost per quality adjusted life 
year (QALY) gained when they were both calculated for the same economic evaluation. 
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per QALY gained result as well. The methodological quality of the studies was good (55%) or very good 
(26%). A total of 124 cost per LYG results were obtained with a mean ratio of 49,529€ and a median of 
11,490€ (standard deviation of 183,080). Since 2003, a commonly-accepted Spanish threshold has 
been referenced by 66% of studies. A significant correlation was found between the cost per LYG and 
cost per QALY gained results (0.89 Spearman-Rho, 0.91 Pearson). 
Conclusions: There is an increasing interest for economic healthcare evaluations in Spain and the 
quality of the studies is also improving. Although a commonly-accepted threshold exists, further 
information is needed for decision making as well as to identify the relationship between the costs per 
LYG and per QALY gained. 
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Reviewers' comments: 
 
Reviewer #1: 
 
The manuscript EJHE-D-10-00140 is an interesting contribution to an important methodologic 
discussion, i.e. outcome measurement within the framework of health economic studies by means of 
life years gained (LYG) and cost per quality adjusted life year (QALY). The authors conducted a 
systematic review which aims at assessing the methodological quality of the increasing number of 
health economic evaluations in Spain and at investigating the relationship between the cost per LYG 
results and the cost per QALY. An additional analysis focuses on the question whether the 
recommended cost per LYG threshold published in Spain in 2002 has had an impact on afterwards 
published health economic evaluations. 
 
In the discussion section (p. 6, line 37f) the authors state that "the number and quality of published 
Spanish health economic evaluations seems to improve as years go by". In order to support this 
statement, quality criteria are pointed out in the same paragraph. The authors argue that "in past 
reviews" certain standards or quality criteria were not sufficiently met. This finding should be 
described in greater detail in the results section. Is there a break-even point, for instance a specific 
publication date of a study or a review, which marks the onset of the quality gain in health economic 
assessments in Spain? Or is it a continuous process of quality improvement? This point should be 
described more precisely. 
 
RESPONSE:  
 
We now state in the section ICER analysis: 
 
"However, a review by Sacristán et al. in 2002 found that most economic evaluations that 
recommended the adoption of a certain health intervention were based on ICE lower than 30,000 € per 
LYG [12]. This commonly-used threshold has been extended to cost per QALY and strengthened by the 
opinion of expert Spanish health economists [13]." Page 4 line 16 
 
In the Results section we now state:  
"Compared to previous systematic Spanish reviews [1,4], some methodological aspects seem to have 
improved. First, 82% of studies reviewed stated the perspective of the evaluation, compared to 28 and 
43%, respectively, in previous reviews [1,4]. Second, the incremental cost and LYG differences are 
shown together with incremental ratios in 84% of studies. Third, 97% of studies conducted some form 
of sensitivity analysis, an essential requirement for any good economic evaluation, compared with only 
30-68% [1,4] of past reviews. And fourth, although only 47% of studies stated the source of financing, 
this is greater than the 29% found in past reviews [4]." Page 7, line 21 
And:  
"As previously stated, a review published in 2002 found that most studies considered technologies 
with an incremental cost-effectiveness ratio below 30,000€ as efficient [12]. Our review showed that, 
since 2003, this unofficial threshold has been explicitly used as a reference by 66% of studies 
included."  Page 9, line 10 
 
In the Discussion section we now state:  
 
"Analysis of the methodological quality of the studies published since 2003, showed that 86% (30 of 35) 
were rated as (code++ or code +), showing the possible influence of previously published reviews in 
2002 [1,12] that may have led to greater methodological rigor. Moreover, it should be expected that the 
recent publication of Spanish recommendations on the economic evaluation of health technologies [11] 
will reinforce this trend in the future." Page 11, line 6. 
 
END RESPONSE 
 
Another main critique is the following: At first sight, the significant correlation between cost per LYG 
and cost per QALY seems to be self-evident. Though, this correlation may vary across different types of 
diseases. The authors, being aware of this aspect, give examples for such as cancer and chronic illness 
(p. 7, line 46ff). Nevertheless, it is doubtful whether the statistical approach of this study is suitable for 
differentiating between the various illness conditions. The predominating impression after having read 
the paper is that the analyses equalize these differences rather than accentuating them. 
 
RESPONSE: 
We agree with the reviewer. We have added some points in the Discussion on this issue, and now 
conclude that:  
 
"Therefore, larger studies where the primary objective is to analyse the relationship between ICE 
thresholds and types of diseases would be necessary. In the present study, only 9 out of 58 results, 
corresponding to 4 studies, showed this discrepancy, which is not sufficient to reach any conclusions." 
Page 13, line 25. 
 
END RESPONSE. 
 
Reviewer #2: 
 
Dear Editor/Dear Authors 
The Manuscript Number EJHE-D-10-00140 "The use of cost per life year as cost Effectiveness Gained 
measure result in Spain. A recent publications review" is an interesting exercise in two complementary 
dimensions: first, it can provide guidance on the threshold of acceptability implicitly used in Spanish 
economic evaluation of health interventions, and second, it can provide answers to whether the 
Spanish authors have accepted the threshold discussed by Sacristán et al in 2002. 
 
In my opinion, the authors commit two conceptual errors that influence the development of the 
manuscript. 
 
First, Sacristán et al. (2002) did not suggest or advocate that the threshold of acceptability 
(incremental cost per additional life year gained) should be set at ? 30,000 / LYG. Sacristán et al., 
reviewed the Spanish papers on economic evaluation of health care interventions published from 1990 
to 2000 and analyzed the 
recommendations of the authors of these works on what is supposed to be worth the incremental cost 
effectiveness ratio efficiently. Therefore, a part of the work of the authors of the manuscript EJHE-D-
10-00140 had already been made by Sacristán et al. (2002). 
 
Secondly, it is wrong to cite that "Later threshold cost per QALY extended to by the Spanish Health 
Economics Association [13] ...." The threshold of 30,000 ?/LYG has been never adopted or recognized 
by the Spanish Health Economics Association in the debate on the need for greater use of economic 
evaluation studies in healthcare decision making (http://www.aes.es/Publicaciones/AESEE2.pdf). The 
reference 13 is only the opinion of a member of the Spanish Health Economics Association issued 
individually, not on behalf of the Spanish Health Economics Association. 
 
Therefore, my recommendation is that the manuscript EJHE-D-10-00140 was accepted for publication 
on 
condition that (a) the authors should carry out major changes in the manuscript and (b) the authors 
should focus their aim to respond if the threshold discussed in the work of Sacristán et al (2002) of ? 
30,000 / LYG has been adopted as a reference in Spanish papers published in later years (from 2003 
until now) or not. 
 
 
RESPONSE: 
 
We agree with the reviewer that no threshold was suggested either in the paper by Sacristan nor in any 
statement by the Spanish HEA and have revised the manuscript to emphasize this. We also include new 
material that addresses the question of whether the threshold suggested by Sacristán el al. have been 
adopted or has influenced Spanish papers published subsequently. 
 
END RESPONSE. 
 
 
More specifically: 
 
1) The review of economic evaluation studies carried out between 1990 and 2000 was yet conducted 
by 
Sacristán et al. (2002). Authors are encouraged to focus their review in the period following the 
publication of the work of Sacristán et al., ie the period 2003-2009. The opposite is repeat work 
already done and published. 
 
RESPONSE: 
 
We agree with the reviewer that, to some extent, we have 'repeated' the review by Sacristán et al 
(2002), since we cover the period already analyzed in that paper. However, we believe that considering 
all economic evaluations (including those published before 2002) enabled us to better analyze the 
evolution of some aspects, such as the methodology quality of the studies or the potential influence of 
certain key publications like that by Sacristán et al. (2002). It also provides a larger sample size that 
may help in some of the analyses carried out. 
 
END RESPONSE. 
 
2) It would be interesting to include studies using the QALY as an outcome, since in the Spanish debate 
on the desirable value of the threshold, the figure of 30,000 euros has been used as a reference of a 
good value for a QALYs (eg reference 13). 
 
RESPONSE: 
 
A companion study using QALYs has already been carried out by Rodriguez-Barrios et al (2011, in 
press), the first author of the present study. Since C/LYG is also a commonly used C/E ratio, in this 
paper we wanted to focus on studies using C/LYG and introduce the comparison between this and 
C/QALY when both ratios where available (Rodriguez JM, Paz S, Lizan L, Gonzalez P. The use of Quality 
Adjusted Life Years (QALYs) in the economic evaluation of health technologies in Spain: a review of the 
1990-2009 literature. Value in Health 2011 Volume 14 Issue 4.) 
 
In the Discussion section we now state: 
 
"One limitation of this study is the narrow focus on methodologies using cost per LYG as a result. 
However, we believe that a detailed examination of this particular topic was desirable, since a similar 
review focused on the results of studies using cost per QALY has been published elsewhere [5]." Page 
11, line 13. 
 
END RESPONSE. 
 
3) The authors should be used as an element to consider whether in the studies reviewed made explicit 
references to the article of Sacristán et al. (indicating that the authors knew the threshold discussed) 
and if the authors explicitly compare their results with the threshold discussed by Sacristán et al. 
(2002). Finally, another item to discuss would be whether the authors' recommendations were based 
on a comparison of the results of their studies with the threshold of ?30,000 per LYG or ?30,000 per 
QALY. In most of the studies cited so it is. And this is a strong argument in favour of the endogenization 
of the threshold of 30,000 euros in the Spanish framework of the economic evaluation of health care 
technologies, contrary to what is suggested as a main conclusion of the manuscript. 
 
RESPONSE:  
 
In the Results section we now state: 
"As previously stated, a review published in 2002 found that most studies considered technologies 
with an incremental cost-effectiveness ratio below 30,000€ as efficient [12]. Our review showed that, 
since 2003, this unofficial threshold has been explicitly used as a reference by 66% of studies 
included." Page 9, line 10. 
 
In the Discussion section we now state: 
 
"Analysis of the methodological quality of the studies published since 2003, showed that 86% (30 of 35) 
were rated as (code++ or code +), showing the possible influence of previously published reviews in 
2002 [1,12] that may have led to greater methodological rigor. Moreover, it should be expected that the 
recent publication of Spanish recommendations on the economic evaluation of health technologies [11] 
will reinforce this trend in the future."  Page 11, line 6 
And 
"Different thresholds have been stated in Spanish publications (ranging from 30,000€ to 
50,000€/QALY) [12,21,22], but a recommendation of 30,000€/QALY gained is commonly considered 
as cost effective for most authors after the review by Sacristán et al. in 2002[12]." Page 12, line 10. 
 
END RESPONSE. 
 
4) It would be necessary to include control variables in the analysis or perform sensitivity analysis: Is it 
feasible to compare the results and findings of studies where the source of funding is private or where 
one or several authors works at private companies to the results and conclusions of studies where the 
source of funding is public or where the authors works at public organizations? Is it possible to 
compare the results and conclusions of the papers published in journals indexed in the Journal of 
Citation Report with those who are not? 
 
RESPONSE: 
 
We now state in the Results section: 
"Analysis of the cost per LYG of all studies reviewed according to the source of funding showed that 
robust mean results were quite similar (11,539€ for privately-funded studies, 18,855€ for publicly-
funded studies and 13,069€ for studies without the source of funding stated). However, this 
comparison is biased due to the small number (3) of  publicly-funded studies." Page 9, line 4.  
We were not able to compare studies appearing in indexed and non-indexed journals because only 19 
of the 124 cost per LYG results were from studies published in non-indexed journals. 
 
END RESPONSE. 
 
5) Similarly, the authors should discuss the potential existence of publication bias in the field of 
economic 
evaluation when the cost-effectiveness ratio found is very high. The manuscript would benefit from a 
thorough discussion on this topic. 
 
RESPONSE: 
 
We now state in the Discussion section: 
 
"We found no clear influence of the commonly-used cost per LYG threshold of 30,000€ in studies 
published after the article by Sacristán et al (2002). However, an increase in the number of studies 
with cost per LYG results close to, but below, the 30,000€ threshold was found, which might indicate a 
certain temporary publication bias caused by the implicit acceptance of a threshold of efficiency, 
although more information would be needed to reach definitive conclusions." Page 12, line 14. 
 
END RESPONSE. 
 
Minor comments: 
 
Authors should review the manuscript and correct some typos. 
 
RESPONSE: 
 
The manuscript has been revised by an English native medical translator. 
 
END RESPONSE. 
 
I would like to stress that if the manuscript is reviewed according to these suggestions, the work will 
be of great interest not only for Spanish readers, as he delves into a very important issue for European 
health policy makers as the endogenization of explicit or implicit thresholds of acceptability in the field 
economic evaluation is. 
 
I hope these comments are useful to the Editor and Authors 
 
Yours sincerely 
 
 1 
INTRODUCTION 
Economic evaluation provides information to healthcare professionals, decision-makers and consumers in 
general about the efficiency (the relation between cost and effects) of health technologies that may aid the 
choice of the most-favourable option [1]. Health technology is defined as any kind of drug, device and 
medical or surgical procedure used in healthcare management. The development of new health 
technologies, whose aim is to improve general health by reducing mortality and morbidity and increasing 
the quality of life, involves costs for the society and for healthcare providers [2]. The scarcity of available 
resources and the increasing demand for health care requires more- rational assignment of resources and 
better definition of priorities: in this scenario, economic evaluation may provide valuable information [3]. 
Economic evaluation of health technologies has been increasing over recent decades in Spain, as 
evidenced by systematic reviews of Spanish economic healthcare evaluations [1,4,5]. However, these 
studies also point out some methodological aspects to be improved, including the definition of the 
perspective used in the study or the inclusion of sensitivity analyses, among others. 
Textbooks and guidelines on health economic evaluation typically distinguish four different types of 
evaluation: cost-benefit analysis, cost-utility analysis (CUA), cost-effectiveness analysis (CEA) and cost-
minimization analysis [6]. Each deals with costs but differs in the way the consequences of health care 
programs are measured and valued [7]. In cost-benefit analysis, both costs and consequences are 
measured in monetary units, while in cost-minimization analysis only costs are measured considering the 
same consequences between comparators. In CEA, consequences are measured in natural units (life years, 
events prevented, percentage of success) while in CUA, life years are adjusted by quality. 
CEA is the most-frequently used type of economic evaluation in Spain, together with CUA [8]. In CEA, 
health outcomes are measured in units of effectiveness, frequently disease-specific, which may be 
considered as intermediate or final outcomes. When comparing different health technologies using 
intermediate outcomes, only the same kind of effectiveness measures and final outcomes, such as life 
years gained (LYG), offer relevant information to decision makers.  
The objective of this study was to evaluate the methodological characteristics of CEA carried out in Spain 
since 1990 which include LYG as an outcome to measure the incremental cost-effectiveness ratio (ICER). 
Secondary objectives were first, to determine whether the cost per LYG results were influenced by a 
commonly-accepted cost-effectiveness threshold and second, to assess possible differences in study 
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 2 
conclusions where quality adjusted life years (QALY) gained were also reported as an outcome measure 
together with LYG. 
 
METHODS 
A systematic review of published studies on the economic evaluation of health technologies in Spain 
including LYG as an outcome measure was conducted in PubMed/Medline and the CRD database (March 
2009).  
The following combinations of terms were applied to the PubMed/Medline database: ("Cost-Benefit 
Analysis"[Mesh] OR "Models, Economic"[Mesh] OR "Costs and Cost Analysis"[Mesh] OR 
"Economics"[Mesh]) AND (Spain OR Spanish) AND (qaly OR avac OR lyg OR avg OR "life saved" OR 
"life year saved" OR "life gained" OR "vida salvada" OR "año de vida ganado" OR "life year gained" OR 
"life-years gained" OR "year of extended life"). The systematic review was limited to evaluations 
involving humans and whose publication language was Spanish or English. 
The search strategy for the CRD database combined the following terms: “Spain” AND “cost 
effectiveness” AND (“life year gained” OR “life year saved”) NOT “review”. 
We searched other relevant local publications by hand, including “Revista Española de Economia de la 
Salud”, “Pharmacoeconomics Spanish Research Articles”, “Revista Española de Enfermedades 
Metabólicas Óseas”, “Angiología” or “Vacunas”. 
 
Inclusion and exclusion criteria 
Articles were selected according to the following inclusion criteria, a) studies conducted in the Spanish 
context; b) studies published in either Spanish or international journals; c) studies related to economic 
evaluation of health technologies; d) study results had to include a cost-effectiveness analysis expressed 
in cost per LYG; e) studies referred to either adult or paediatric populations; f) studies conducting an 
incremental cost-effectiveness analysis. 
Studies were excluded if a) they included QALYs and not LYG as an outcome measure; b) study results 
did not include an incremental cost-effectiveness ratio; c) the study was a systematic review. 
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Quality assessment 
To assess the methodological quality of articles, a criteria checklist was developed as an adaptation of the 
criteria checklist for economic evaluations recommended by the National Institute of Health and Clinical 
Excellence [9], assigning a score of Code (-), Code (+) or Code (++) to value the methodological quality 
of studies. The criteria suggested by the Oxford Centre for Evidence Based Medicine [10] for economic 
and decision analysis were also applied to rank the validity of the evidence. 
 
ICER analysis 
The ICER is the most frequently-used method of comparing treatment alternatives or clinical pathways in 
economic evaluations of healthcare. Different healthcare authorities have adopted a maximum ICER 
threshold to help decide whether a health technology is cost-effective or not and whether it should be 
adopted by the healthcare system. In Spain, there is no official threshold recommended by healthcare 
authorities as a “rule-of-thumb” for the economic evaluation of health technologies [11]. However, a 
review by Sacristán et al. in 2002 found that most economic evaluations that recommended the adoption 
of a certain health intervention were based on ICER lower than 30,000 € per LYG [12]. This commonly-
used threshold has been extended to cost per QALY and strengthened by the opinion of expert Spanish 
health economists [13]. However, the adoption of a fixed threshold could result in economic studies 
seeking the maximum price for the technology assessed that still shows a cost-effectiveness ratio below 
the threshold [14]. 
Our review also identified studies that calculated cost-effectiveness results in terms of both LYG and 
QALYs gained in order to determine whether, considering the threshold of 30,000€ per QALY/LYG, they 
yield the same conclusion or there were differences [15]. The analysis used a dispersion graph comparing 
cost per LYG and cost per QALY gained in relation to the cost-effectiveness threshold. 
The cost-effectiveness results of studies reviewed were updated to 2009 Euros using the inflation rates 
stated by the National Statistics Institute [16] and the corresponding exchange rates when necessary. In 
order to normalize the results taking into account biased and asymmetric data, a Box-Cox transformation 
of cost-effectiveness data using the natural logarithm was carried out [17]. 
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RESULTS 
Our search yielded a total of 201 references, 62 of which were finally included according to the inclusion 
and exclusion criteria (Fig.1, table 1). 
 
[Figure 1 Selection process] 
 
The oldest study selected was published in 1993 and the latest was published in March 2009, with 76% of 
studies being published from 2002 onwards (Fig.2).  
 
[Figure 2, Annual distribution of the studies included] 
 
A total of 58% of studies were published in Spanish journals and 42% in international journals. Four 
studies were in paediatric populations, four in paediatric and adult populations (vaccination studies) and 
the remaining 87% in adult patients. Sixty-five percent compared therapeutic interventions while the rest 
dealt with preventive strategies (four related to screening programs). The studies were conducted for 
cardiovascular diseases (31%), oncology (23%), infectious diseases (11%), respiratory diseases (11%), 
smoking (8%), hepatitis (6%), diabetes mellitus (5%) and musculoskeletal disorders (5%).  
The most-frequently used perspective was that of the Spanish National Health System (69%). The societal 
perspective was only used in five studies (in four together with the National Health System perspective). 
In two articles the authors stated a societal perspective but did not consider indirect costs. The perspective 
of the evaluation was not stated in 11 articles (18%). 
The currency and year for unit values was acknowledged in 81% of studies, and only the currency in the 
remaining studies. The currencies most-used were the Euro (n=46) followed by the Spanish Peseta (n=8), 
US Dollar (n=7) and the Ecu (European Currency Unit before 1999) in one study. 
Seventy-four percent of studies discounted costs and effects, 10% discounted only costs, 6% only effects, 
and the remaining studies applied no discount. Only 44% of studies justified why discounting was 
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 5 
necessary and why a specific discount rate was applied. The most-common discount rate used was 3% 
(42%), followed by 5% (25%), 6% (13%), 3.5% (9%), 4% (one study) and 4.25% (one study). In 89% of 
studies, the discount rate was the same for costs and health benefits. 
The robustness of the results was tested by sensitivity analysis in 97% of studies, with one-way sensitivity 
analysis being used in 58% of studies, other methods such as multivariate or probabilistic sensitivity 
analysis together with one-way sensitivity analysis in 19%, multivariate analysis alone in 15% and 
probabilistic sensitivity analysis alone in 5%. 
The ICERs were clearly stated in 84% of studies by calculating the cost and effect differences between 
the comparators evaluated. In the remaining studies, the incremental cost-effectiveness was stated without 
showing the differences in costs and effects. 
In 74% of studies, the authors acknowledged the limitations of the study. The source of funding was 
stated in 47% of studies, of which 90% were privately funded. Only three studies were publicly funded, 
none since 2004. 
The level of evidence of 76% of studies was considered as 3b (analysis based on limited alternatives or 
costs, poor quality estimates of data, but including sensitivity analyses incorporating clinically-sensitive 
variations) due to the diverse nature of the sources used to estimate costs and effects, and because 
sensitivity testing relied only on one-way analyses. Ten studies (16%) were assigned a 2b level of 
evidence (analysis of the effectiveness based on limited review(s) of the clinical evidence or single 
studies; and including multi-way sensitivity analyses) and five studies (8%) were considered level 4 (no 
sensitivity analysis included). 
The methodological quality was considered to be good (Code +) in 55% of studies, very good (Code ++) 
in 26% and not good (Code -) in 19%.  
Compared to previous systematic Spanish reviews [1,4], some methodological aspects seem to have 
improved. First, 82% of studies reviewed stated the perspective of the evaluation, compared to 28 and 
43%, respectively, in previous reviews [1,4]. Second, the incremental cost and LYG differences are 
shown together with incremental ratios in 84% of studies. Third, 97% of studies conducted some form of 
sensitivity analysis, an essential requirement for any good economic evaluation, compared with only 30-
68% [1,4] of past reviews. And fourth, although only 47% of studies stated the source of financing, this is 
greater than the 29% found in past reviews [4]. 
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[Table 1 Description of the studies included] 
 
ICER analysis 
A total of 124 cost per LYG results were obtained from the 62 economic evaluations included in our 
study. The number of LYG results exceeds the number of studies included due to different sub-analyses 
of, for example, different time horizons, patient groups or comparators in the same study. Four (3%) LYG 
results showed a dominant situation for the intervention analyzed (lower costs and greater effectiveness 
than the alternative compared) while the rest resulted in a mean cost per LYG of 49,529€ and a median of 
11,490€. The great diversity of the evaluations with respect to pathologies, patients and methodologies 
resulted in wide dispersion of the results (standard deviation of 183,080). Therefore, more-robust 
statistical techniques were applied, such as the Huber estimator [18]. The robust mean calculated using 
the Huber estimator was 12,515€. Where classical statistical techniques fail to cope well with deviations 
from a standard distribution, robust statistical methods provide tools for statistical problems in which 
underlying assumptions are inexact. Huber’s M-estimator, a generalization of maximum likelihood 
estimators, allows data to be described with reduced weighting of outliers. The most widely-used 
weighting factor for Huber’s M-estimator is 1.339 (Table 2). 
 
[Table 2. Description of ICER results.] 
 
Analysis of the cost per LYG of all studies reviewed according to the source of funding showed that 
robust mean results were quite similar (11,539€ for privately-funded studies, 18,855€ for publicly-funded 
studies and 13,069€ for studies without the source of funding stated). However, this comparison is biased 
due to the small number (3) of publicly-funded studies. 
As previously stated, a review published in 2002 found that most studies considered technologies with an 
incremental cost-effectiveness ratio below 30,000€ as efficient [12]. Our review showed that, since 2003, 
this unofficial threshold has been explicitly used as a reference by 66% of studies included. 
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[Figure 3. Year of study and cost per LYG results.] 
 
Of the 62 studies with cost per LYG results, 24 also calculated the cost per QALY gained. A total of 58 
results of cost per LYG and QALY gained were represented in a dispersion graph to analyze whether the 
two results provided the same conclusions. In 84% of comparisons, the two results yielded the same 
conclusion, in 40 cases (69%) the results were below the 30,000€ threshold showing the intervention to 
be cost effective, and in 9 cases (16%) the results were above the threshold. However, in 4 cases (3 from 
the same study) the cost per LYG was below the 30,000€ threshold whilst the cost per QALY gained was 
above it. The other 5 cases (3 from the same study) showed the opposite results (Fig. 4).  
 
[Figure 4. Study of cost per LYG and cost per QALY gained.] 
 
The Spearman-Rho correlation was used to correlate the estimate between the quantitative characteristics 
of the cost per LYG and cost per QALY gained. This rank-correlation method is considered robust 
against outliers and non-normal data distribution. The Spearman rank correlation between the two cost-
effectiveness results was 0.89 (p<0.001). After log transformation, the Pearson correlation was used, with 
a result of 0.91 (p<0.001). 
 
DISCUSSION 
Interest in economic evaluations in health care and their contribution to decision making has increased in 
Spain in recent years [1,4,12]. We conducted a review of economic evaluations of health technologies in 
Spain assessing the incremental cost per LYG as an outcome from 1993 until the beginning of 2009. The 
number of publications found reflects this increasing interest.  
Of the studies reviewed, only one assessed the cost per LYG for a medical device, with the remaining 
articles assessing mainly drugs or healthcare programs. As medical devices are used to provide 
symptomatic improvement, the number of QALY gained is the preferred assessment outcome. 
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The methodology used by the majority of studies assessed satisfied most of the general methodological 
aspects considered to represent good practice in international recommendations [3,8,9,10,11]. Compared 
with previous reviews [1,4] the number and quality of published Spanish health economic evaluations 
seems to have improved over times, and some deficiencies found in previous reviews seem to have been 
solved. Analysis of the methodological quality of the studies published since 2003, showed that 86% (30 
out of 35) were rated as (code++ or code +), showing the possible influence of previously published 
reviews in 2002 [1,12] that may have led to greater methodological rigor. Moreover, it should be expected 
that the recent publication of Spanish recommendations on the economic evaluation of health 
technologies [11] will reinforce this trend in the future.  
One limitation of this study is the narrow focus on methodologies using cost per LYG as a result. 
However, we believe that a detailed examination of this particular topic was desirable, since a similar 
review focused on the results of studies using cost per QALY has been published elsewhere [5]. In 
addition, despite a comprehensive search, some of the earliest publications may have been overlooked, 
although their inclusion would have been unlikely to alter the reported findings. 
Some problems arise in the increasing use of cost-effectiveness thresholds as an explicit decision-making 
rule. Cost-effectiveness thresholds may vary according to the country or geographical area; in fact, the 
World Health Organization recommends adjustment by the corresponding gross domestic product [19]. 
They may also vary according to the decision maker (social or health provider perspective), the healthcare 
technologies compared (preventive or therapeutic), the effectiveness measure of the evaluation chosen 
(LYG, QALY gained, intermediate clinical outputs) or the disease under study. As an example, recent 
supplementary advice for appraising life-extending, end-of-life treatments made by NICE [20] recognized 
the need for further appraisal when the treatment involved is indicated for small populations with 
incurable illnesses and the most-plausible reference case point estimate for the ICER exceeds the upper 
threshold of the range normally considered.  
Cost-effectiveness thresholds are not gathered unanimously in the different international guidelines for 
health economic evaluation, and the latest Spanish recommendations [11] do not state any explicit 
thresholds, in contrast with NICE guidelines (25,000-35,000£/QALY gained)[9]. Different thresholds 
have been stated in Spanish publications (ranging from 30,000€ to 50,000€/QALY) [12,21,22], but a 
recommendation of 30,000€/QALY gained is commonly considered as cost effective for most authors 
after the review by Sacristán et al. in 2002[12].  
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We found no clear influence of the commonly-used cost per LYG threshold of 30,000€ in studies 
published after the article by Sacristán et al (2002). However, an increase in the number of studies with 
cost per LYG results close to, but below, the 30,000€ threshold was found, which might indicate a certain 
temporary publication bias caused by the implicit acceptance of a threshold of efficiency, although more 
information would be needed to reach definitive conclusions. 
Other decision sources, such as the potential financial consequences of a new healthcare technology, are 
not covered by cost-effectiveness thresholds and represent an essential part of a comprehensive economic 
assessment of a healthcare technology. Budget impact analysis is used to quantitatively estimate the 
foreseen changes in healthcare expenses for treatment of a specific pathology when an alternative 
intervention is introduced [23,24], complementing the information provided by the cost-effectiveness 
results of the new intervention. 
When two types of final outcome results are studied (LYG and QALY gained) in the same health 
economic evaluation, the conclusions of the study do not depend on the final outcome chosen in most of 
the cases, i.e., the cost per LYG and the cost per QALY gained result led to the same conclusion. The 
high correlation found in our study between the two ratios (0.89 Spearman and 0.91 Pearson correlation) 
is similar to that found by Chapman in 2004 (0.86 Spearman and 0.84 Pearson correlation) [15]. This is 
important because it is often difficult and costly to find utility data for QALY calculation. However, 
further assessment would be needed to accept this as a fact, and it should be noted that this correlation 
may vary between different types of diseases. In some cases, choosing LYG or QALY as the outcome of 
the study may change the cost-effectiveness results of an evaluation. An intervention could be cost-
effective considering cost per LYG rather than cost per QALY gained when it involves a better survival 
outcome but has less quality of life effectiveness (for example, having more side effects, disease 
complications, survival rates in a severe health state). This would be the case for certain cancers, where 
life years are gained when disease severity is associated with low levels of quality of life (for example 
breast cancer in the studies reviewed [25]). The opposite could occur in an intervention in which the 
quality of life is greatly improved but there is a limited improvement in survival. This would be the case 
for chronic pathologies with good life expectancy but which are highly-sensitive to quality of life changes 
associated with improvements related to a new treatment option resulting in fewer disease complications 
or side effects, such as hepatitis C [26] or type 2 diabetes [27]. Therefore, larger studies where the 
primary objective is to analyse the relationship between ICER thresholds and types of diseases would be 
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necessary. In the present study, only 9 out of 58 results, corresponding to 4 studies, showed this 
discrepancy, which is not sufficient to reach any conclusions. 
Cost-effectiveness analysis is useful in allowing decision makers to maximize resource allocation. 
Although different approaches have been used to present results (LYG, QALYs, etc), the best alternative 
may depend on the scope of the study, the disease evaluated and the financial impact of the technologies 
under evaluation, among other factors. 
Our results suggest that some aspects should be improved in future studies using LYG as an effectiveness 
outcome: a) a clear definition of the perspective of the economic evaluation; b) a description of ICER in 
all economic evaluations performed, and c) greater use of probabilistic sensitivity analysis to better 
evaluate uncertainty. 
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Tables and figures 
Table 1: Description of the studies included 
 
Reference Objective 
Type of 
evaluation 
Type of 
intervention 
Results Quality 
NICE
a
 
Quality 
CEBM
b
 
Cairols-Castellote 
MA, 2009 [28] 
To assess the cost-effectiveness of 
endovascular treatment for the treatment of 
abdominal aortic aneurysm with respect to 
open surgery. 
CEA-CUA Therapeutic 
device 
 19,852€/LYG (4 years) 
 27,077€/QALY (4 years) 
 111,064€/LYG (1 year) 
 137,206€/QALY (1 year) 
Code + 2b 
Martín-Jiménez M, 
2009 [29] 
Cost-effectiveness analysis of docetaxel vs. 
5-fluorouracil in combined therapy in the 
initial phases of breast cancer 
CEA - CUA Therapeutic  2,545€/LYG 
 2,855€/QALY 
 
Code + 3b 
Oliva J, 2009 [30] To asses the cost-effectiveness of a genetic 
screening program for first-degree relatives 
of patients with familial 
hypercholesterolemia compared with the 
alternative of no screening. 
CEA Preventive 
(screening) 
 3,714€/LYG Code ++ 2b 
Alonso R, 2008 
[31] 
To evaluate the cost-effectiveness of 
different preventive strategies in familial 
hypercholesterolemia in comparison with 
routine practice: Atorvastatin monotherapy 
(40 mg or 80 mg), atorvastatin combined 
with ezetimibe 10 mg (A40+E10 or 
A80+E10) 
CEA Preventive  3,268€/LYG (Atorvastatin 40mg vs 
Clinical practice) 
 5,697€/LYG (Atorvastatin 
40mg+Ezetimibe 10mg vs Clinical practice) 
 1,976€/LYG (Atorvastatin 80mg vs 
Clinical Practice) 
 4,363€/LYG (Atorvastatin 
80mg+Ezetimibe10mg vs Clinical Practice) 
Code + 3b 
Fernández de 
Bobadilla J, 2008 
[32] 
To analyse the efficiency of varenicline 
compared with bupropion, nicotine 
replacement therapy and no 
pharmacological treatment. 
CEA – CUA Therapeutic Dominant Code ++ 3b 
Grupo de Cost-effectiveness of maintenance CEA-CUA Therapeutic  8,974€/LYG Code ++ 3b 
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Farmacoeconomía 
del Linfoma 
Folicular, 2008 [33] 
treatment with rituximab compared to no 
medication in resistant or recurrent 
follicular lymphoma patients. 
 9,888€/QALY 
Largeron N, 2008 
[34] 
To assess the health and economic impact 
of implementing a four-valent HPV vaccine 
alongside existing screening versus 
screening alone. 
CEA-CUA Preventive  9,147€/LYG 
 6,860€/QALY 
Code + 3b 
Maroto P, 2008 [35] To evaluate the cost-effectiveness of 
sorafenib plus best supportive care (BSC) 
versus BSC alone in advanced renal cell 
carcinoma. 
CEA Therapeutic  22,850€/LYG (Lifetime) 
 166,113€/QALY (1 year) 
Code + 3b 
Mayordomo J, 2008 
[36] 
To evaluate the cost-effectiveness of 
pegfilgrastim 6 mg compared with 
filgrastim in 45-year-old women with stage 
II breast cancer in the primary prophylaxis 
of febrile neutropenia. 
CEA-CUA Preventive  13,365€/LYG 
 14,128€/QALY 
Code + 3b 
Paz-Ares L, 2008 
[37] 
To assess the cost-effectiveness of sunitinib 
vs best supportive care in patients with 
metastatic and/or unresectable 
gastrointestinal stroma tumours as a second-
line treatment. 
CEA-CUA Therapeutic  30,665€/LYG 
 49,777€/QALY 
Code + 3b 
Aballéa S, 2007 
[38] 
The impact of an increase in vaccination 
uptake, from the current level to a similar 
level as that currently achieved in people 
aged over 65, on costs and on health 
outcomes. 
CEA-CUA Preventive  10,950€/LYG (SNHS perspective) 
 16,788€/QALY (SNHS perspective) 
 3,045€/LYG (societal perspective) 
 4,669€/QALY (societal perspective) 
Code + 3b 
Badía X, 2007 [39] To analyze the cost-effectiveness of 
enfuvirtide plus optimized therapy in HIV 
patients. 
CEA Therapeutic  29,127€/LYG Code ++ 2b 
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Casado MA, 2007 
[40] 
Cost-effectiveness analysis of first line 
therapy in patients with metastatic 
colorectal cancer. 
CEA Therapeutic  157,565€/LYG Code + 2b 
 
Fernández de 
Bobadilla J, 2007 
[41] 
To assess the cost-effectiveness of 
atorvastatin 10mg vs placebo using data 
from the ASCOT lipid-lowering arm. 
CEA Therapeutic  11,614€/LYG Code ++ 2b 
Lázaro P, 2007 [42] To evaluate the cost-effectiveness of 
palivizumab in preventing respiratory 
syncytial virus infection in high risk 
children. 
CEA-CUA Preventive  All children : 19,945€/LYG and 
14,630€/QALY 
 Premature infants: 17,609€/LYG and 
12,899€/QALY 
 Infants with chronic disease: 
25,352€/LYG and  18,617€/QALY 
Code ++ 3b 
López JM, 2007 
[43] 
Economic evaluation of use of the 
tetravalent vaccine in cancer prevention. 
CEA Preventive  5,724€/LYG Code + 3b 
Piñol C, 2007 [44] To assess the cost-effectiveness of the 
addition of acarbose to existing treatment in 
patients with type 2 diabetes mellitus. 
CEA-CUA Therapeutic  2,253€/LYG 
 2,475€/QALY 
Code + 
 
3b 
Cornuz J, 2006 [45] To estimate the incremental cost-
effectiveness of first-line 
pharmacotherapies for smoking cessation. 
CEA Therapeutic  Gum vs Physician Counselling: 
4,247€/LYG and 2,810€/QALY 
 Patch vs Physician Counselling: 
3,348€/LYG and 2,216€/QALY 
 Spray vs Physician Counselling: 
3,684€/LYG and 2,439€/QALY 
 Bupropion vs Physician Counselling: 
1,671€/LYG and 1,107€/QALY 
Code - 3b 
Fernández de 
Bobadilla J, 2006 
[46] 
To estimate the incremental cost-
effectiveness of atorvastatin 50mg versus 
pravastatin 40mg based on the PROVE-IT 
trial. 
CEA Therapeutic  321€/LYG Code ++ 3b 
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Fernández de 
Bobadilla J, 2006 
[47] 
To perform a cost-effectiveness analysis of 
the use of Atorvastatin 10mg in the primary 
prevention of cardiovascular disease in 
patients with type 2 Diabetes Mellitus. 
CEA-CUA Therapeutic  6,624€/LYG 
 9,054€/QALY  
Code + 3b 
Gil JM, 2006 [25] To compare the efficiency of adjuvant 
therapy with aromatase inhibitors or with 
tamoxifen in postmenopausal women with 
operable breast cancer and positive estrogen 
receptors. 
CEA-CUA Therapeutic  Exemestane vs tamoxifen (study 
2004, 10 years): 36,575€/LYG and 
57,165€/QALY 
 Exemestane vs tamoxifen (study 
2005, 10 years): 44,949€/LYG and 
70,354€/QALY 
 Anastrazole vs tamoxifen (10 years): 
73,494€/LYG and 117,334€/QALY 
 Letrozole vs Placebo 10 years): 
64,284€/LYG and 102,635€/QALY 
 Exemestane vs tamoxifen (study 
2004, 20 years ): 17,518€/LYG and 
32,463€/QALY 
 Exemestane vs tamoxifen (study 
2005, 20 years ): 21,526€/LYG and 
39,802€/QALY 
 Anastrazole vs tamoxifen (20 years ): 
37,451€/LYG and 70,303€/QALY 
 Letrozole vs Placebo (20 years): 
29,345€/LYG and 55,656€/QALY 
Code ++ 3b 
Lamotte M, 2006 
[48] 
To investigate the health economic 
implications of using low-dose aspirin in 
the primary prevention of cardiovascular 
disease. 
CEA-CUA Preventive Dominant Code + 3b 
Lázaro y de 
Mercado P, 2006 
[49] 
To evaluate the cost-effectiveness of 
palivizumab in preventing severe 
respiratory syncytial virus infection in 
premature infants with a gestational age of 
CEA-CUA Preventive  18,023€/LYG (SNHS perspective) 
 15,028€/QALY (SNHS perspective) 
 5,994€/LYG (societal perspective) 
 4,997€/QALY (societal perspective) 
Code ++ 2b 
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32-35 weeks and 2 or more risk factors. 
Lenne X, 2006 [50] To evaluate the epidemiological and socio-
economic consequences of a routine 
childhood vaccination program with 
varicella vaccine. 
CEA Preventive  Vaccine program: 4,481€/LYG 
(SNHS perspective) and 1€/LYG (societal 
perspective), 
 Vaccine program+catch-up: 
14,480€/LYG (SNHS perspective) and 
9,720€/LYG (societal perspective) 
Code ++ 3b 
Shearer AT, 2006 
[27] 
Cost-effectiveness and lifetime diabetes 
consequences of rosiglitazone in 
combination with metformin compared to 
metformin + sulfonylureas or metformin + 
bedtime insulin 
CEA-CUA Therapeutic  Rosiglitazone+metformin vs 
metformin+sulfonylureas: 28,308€/LYG 
and 19,560€/QALY in overweight; 
32,443€/LYG and 28,021€/QALY in obese, 
 Rosiglitazone+metformin vs 
metformin+bedtime insulin: 30,036€/LYG 
and 11,209€/QALY in overweight; 
35,583€/LYG and 13,316€/QALY in obese 
Code + 3b 
Badia X, 2005 [51] To carry out a cost-effectiveness analysis of 
administering clopidogrel in addition to 
standard therapy during the first year of 
treatment in patients with acute coronary 
syndrome but without ST-segment 
elevation. 
CEA Preventive  9,444€/LYG Code ++ 3b 
Buti M, 2005 [52] To estimate the future morbidity, mortality 
and costs of treatment with peginterferon 
alpha-2b plus ribavirin of chronic hepatitis 
C virus infection. 
CEA Therapeutic  Peginterferon alpha 2b+ribavirin vs 
No Treatment (29 year old patients): 
6,850€/LYG 
 Peginterferon alpha 2b+ribavirin vs 
No Treatment (59 year old patients): 
10,027€/LYG 
Code + 3b 
Cannata J, 2005 
[53] 
To carry out an economic assessment of 
Protelos in comparison with placebo to 
determine its cost-effectiveness profile in 
CEA-CUA Therapeutic  21,606€/LYG 
 33,895€/QALY 
Code - 4 
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the treatment of osteoporosis. 
Grau S, 2005 [54] To asses the cost-effectiveness of linezolid 
versus vancomycin for the treatment of 
ventilator associated pneumonia. 
CEA-CUA Therapeutic  Linezolid vs vancomycin: 
1,743€/LYG and 2,095€/QALY, 
 Linezolid vs vancomycin (Gram 
positive): 961€/LYG and 1,158€/QALY, 
 Linezolid vs vancomycin (S, Aureus): 
1,109€/LYG and 1,334€/QALY, 
 Linezolid vs vancomycin (methicillin 
resistant S.Aureus): 337€/LYG and 
405€/QALY 
Code + 3b 
Asensi F, 2004 [55] Evaluate the health outcomes, costs, and 
cost-effectiveness of vaccination with PCV-
7, compared with no vaccination for 
children. 
CEA Preventive  26,189€/LYG Code + 3b 
Balmaña J, 2004 
[56] 
To analyze the benefits and costs of a 
surveillance program to identify individuals 
at risk for hereditary breast and ovarian 
cancer and offer them genetic testing and a 
screening program. 
CEA Preventive 
(screening) 
 4,987€/LYG Code - 3b 
Brosa M, 2004 [57] To analyse the efficiency of hyperlipidemia 
management using atorvastatin versus usual 
care in patients with coronary heart disease 
using data from the GREACE study. 
CEA Therapeutic  5,558€/LYG Code ++ 2b 
Camacho J, 2004 
[58] 
Cost-effectiveness analysis of preventing a 
transfusion pathogen with Advate. 
CEA Preventive  22,124€/LYG Code - 4 
 
Cook JR, 2004 [59] To project the lifetime benefit and cost of 
alternative lipid-lowering treatment 
strategies for coronary heart disease (CHD) 
and non-CHD diabetic patients. 
CEA Therapeutic  Prior to CHD : 19,742 – 30,193€/LYG 
 Diabetic patients non-CHD : 32,516 – 
55,741€/LYG 
Code - 3b 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
 23 
Sacristán JA, 2004 
[60] 
To assess the cost-effectiveness of 
drotrecogin alpha (activated) versus that of 
standard care in the treatment of severe 
sepsis. 
CEA Therapeutic  16,787€/LYG Code + 3b 
Antoñanzas F, 2003 
[61] 
To assess the efficiency of three smoking 
cessation strategies based on 
pharmacotherapies. 
CEA Therapeutic  Bupropion vs physician advice: 
3,652€/LYG 
 Patches vs physician advice: 
1,888€/LYG 
 Gum vs physician advice: 
4,885€/LYG 
Code - 3b 
Buti M, 2003 [62] To evaluate the cost-utility of peginterferon 
alfa-2b plus ribavirin for chronic hepatitis C 
patients. 
CEA-CUA Therapeutic  Peginterferon+Ribavirin800 vs 
interferon: 7,292€/LYG and 3,265€/QALY, 
 Peginterferon+Ribavirin adjusted to 
body weight vs 
Peginterferon+Ribavirin800: 5,425€/LYG 
and 2,291€/QALY 
 Peginterferon+Ribavirin adjusted to 
body weight+compliance vs 
Peginterferon+Ribavirin800: Dominant 
Code - 
 
3b 
Gambús G, 2003 
[63] 
Cost-effectiveness evaluation of fluvastatin 
80 mg/day in coronary heart disease. 
CEA-CUA Therapeutic  17,081€/LYG 
 16,403€/QALY 
Code - 4 
Moreno A, 2003 
[64] 
To perform a cost-effectiveness analysis on 
the use of celecoxib versus traditional non-
steroidal anti-inflammatory drugs in the 
treatment of osteoarthritis. 
CEA Therapeutic  9,932€/LYG Code + 3b 
Nuijten MJ, 2003 
[65] 
Cost-effectiveness of thromboprophylaxis 
with enoxaparin versus no 
thromboprophylaxis in patients with acute 
medical illness. 
CEA 
 
 
 
Preventive  85€/LYG Code + 3b 
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San Miguel R, 2003 
[66] 
To develop a cost-effectiveness analysis of 
therapeutic regimens with interferon-alpha 
and ribavirin in previous interferon non-
responders. 
CEA-CUA Therapeutic  Interferon mono 6 months vs No 
treatment: 24,792€/LYG and 
13,223€/QALY 
 Combo+standard doses of interferon 6 
months vs No treatment: 11,662€/LYG and 
6,079€/QALY 
 Combo+high doses of interferon 6 
months vs No treatment: 11,507€/LYG and 
5,963€/QALY 
 Combo+standard doses of interferon 
12 months vs No treatment: 14,578€/LYG 
and 7,524€/QALY 
Code + 3b 
Hart WM, 2002 
[67] 
To assess a cost-effectiveness analysis of 
the treatment of post-menopausal 
osteoporosis with risedronate and once-a-
week alendronate. 
CEA-CUA Therapeutic  Risedronate vs alendronate: Dominant 
 Risedronate vs no treatment: 
301,351€/LYG and 80,807€/QALY 
 Alendronate vs no treatment: 
625,372€/LYG and 114,290€/QALY 
Code + 3b 
Hart WM, 2002 
[68] 
To calculate the cost-effectiveness of 
adding ramipril to the regular treatment of 
patients at high risk of suffering 
cardiovascular events. 
CEA Therapeutic  13,146€/LYG Code ++ 3b 
Hart WM, 2002 
[69] 
To estimate the cost-effectiveness of adding 
ramipril to conventional treatment in 
patients with heart failure after myocardial 
infarction. 
CEA Therapeutic  1,973€/LYG Code + 2b 
Lindgren P, 2002 
[70] 
To investigate the cost effectiveness of 
exemestane compared to megestrol in post-
menopausal women after tamoxifen failure. 
CEA Therapeutic 
 
 10,330€/LYG Code + 3b 
Llovet JM, 2002 
[71] 
To assess the cost-effectiveness of adjuvant 
therapy while waiting for liver 
CEA Therapeutic  Surgical resection vs standard 
management: 49,665 – 86,913€/LYG  
Code + 2b 
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transplantation in cirrhotic patients with 
early hepatocellular carcinoma. 
 Percutaneous ethanol injection vs 
standard management: 24,832€/LYG 
Plans P, 2002 [72] To evaluate the cost-effectiveness of 
pneumococcal vaccination strategies (23 
serotypes) in the population aged 5 years 
and older. 
CEA Preventive  12,712€/LYG Code + 3b 
Antoñanzas FA, 
2001 [73] 
To measure the cost per year of life saved in 
patients treated with eptifibatide using the 
PURSUIT trial. 
CEA Therapeutic  12,712€/LYG Code - 4 
Soto Alvarez J, 
2001 [74] 
To assess the efficiency of using 
spironolactone in the treatment of chronic 
heart failure when compared with the use of 
conventional treatment alone. 
CEA Therapeutic  4,524€/LYG Code + 3b 
Buti M, 2000 [26] To determine if the incremental sustained 
response rate of combination therapy is 
sufficient to outweigh its extra cost in naive 
patients with histological mild or moderate 
chronic hepatitis C. 
CEA-CUA Therapeutic  Moderate CHC combo 12 months vs 
interferon 12 months (30 years old): 
1,198€/LYG and 787€/QALY 
 Moderate CHC combo 12 months vs 
interferon 12 months (60 years old): 
10,314€/LYG and 3,928€/QALY 
 Moderate CHC combo 12 months vs 
interferon 6 months (30 years old): 
2,850€/LYG and 1,871€/QALY 
 Moderate CHC combo 12 months vs 
interferon 6 months (60 years old): 
19,813€/LYG and 7,546€/QALY 
 Mild CHC combo 12 months vs 
interferon 12 months (30 years old): 
4,063€/LYG and 1,804€/QALY 
 Mild CHC combo 12 months vs 
interferon 12 months (60 years old): 
49,250€/LYG and 7,599€/QALY 
Code ++ 3b 
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 Mild CHC combo 12 months vs 
interferon 6 months (30 years old): 
7,982€/LYG and 3,544€/QALY 
 Mild CHC combo 12 months vs 
interferon 6 months (60 years old): 
87,714€/LYG and 13,533€/QALY 
González-Larriba 
JL, 2000 [75] 
To analyse the cost-effectiveness ratio of 
adjuvant therapy with interferon alpha-2b in 
melanoma patients versus an untreated 
control group. 
CEA Therapeutic  11,473€/LYG Code ++ 3b 
Berger K, 1998 [76] To determine the cost structure of treating 
advanced ovarian cancer and to determine 
the cost-effectiveness of paclitaxel and 
cisplatin as first line chemotherapy. 
CEA Therapeutic  14,958€/LYG Code - 3b 
Comas A, 1998 [77] To study the cost-effectiveness of simple 
anti-smoking advice in primary care. 
CEA Therapeutic  Women: 1,016 – 1,205€/LYG 
 Men: 591 – 784€/LYG 
Code + 3b 
Plans-Rubió P, 
1998 [78] 
To assess the cost-effectiveness of 
treatments for the primary prevention of 
coronary heart disease. 
CEA Preventive  Smoking cessation vs no primary 
prevention: 2,848 – 8,800€/LYG 
 Hypertension treatment vs no primary 
prevention: 7,711 – 138,678€/LYG 
 Hypercholesterol treatment vs no 
primary prevention: 16,912 – 
1,844,481€/LYG 
 Cholesterol diet vs no primary 
prevention: 13,969 – 162,983€/LYG 
Code + 3b 
Plans-Rubió P, 
1998 [79] 
To asses the cost-effectiveness of available 
cardiovascular disease prevention programs 
in Spain. 
CEA Preventive Treating hypercholesterolemia with lovastatin 
and hypertension with hydrochlorothiazide, 
propranolol and nifedipine are the most 
efficient options, 
Code - 4 
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Garuz R, 1997 [80] To perform a cost effectiveness analysis of 
a breast cancer mammography screening 
programme. 
CEA Preventive 
(screening) 
 2,990€/LYG Code + 3b 
Rubió P P, 1997 
[81] 
To assess the cost-effectiveness of a dietary 
treatment of hypercholesterolemia. 
CEA Therapeutic  Dietary vs no dietary in men: 7,111 – 
69,675€/LYG 
 Dietary vs no dietary in women: 
31,829 – 194,442€/LYG 
Code - 3b 
Plans P, 1996 [82] To assess the cost-effectiveness of early 
diagnosis breast cancer. 
CEA-CUA Preventive 
(screening) 
 7,038€/LYG and 7,819€/QALY Code + 3b 
Plans P, 1995 [83] To calculate the cost-effectiveness of 
different smoking cessation methods. 
CEA Therapeutic  Medical advice+gum vs medical 
advice alone: 4,387 – 10,724€/LYG 
 Medical advice+patch vs medical 
advice alone: 5,333 – 12,681€/LYG 
 Medical advice+patch vs medical 
advice+gum: 5,988 – 14,638€/LYG 
Code + 3b 
Plans Rubió P, 1995 
[84] 
To assess the cost-effectiveness of 
pneumococcal vaccination of people aged 5 
years or more. 
CEA-CUA Preventive  8,314€/LYG and 4,322€/QALY Code + 3b 
Plans Rubió P, 1995 
[85] 
To estimate the cost-effectiveness of 
hypolipemiant treatment. 
CEA Therapeutic  33,766 – 469,791€/LYG Code + 3b 
Badía X, 1993 [86] To determine the cost-efficacy analysis of 
treatment with antiendotoxin monoclonal 
antibodies (HA-1A) in adult patients 
admitted to intensive care units. 
CEA Therapeutic  All sepsis: 10,861€/LYG 
 Septic shock: 3,714€/LYG 
Code - 3b 
A Code -, + or ++ score was assigned to the methodological quality of the study according to the nature of the sources used; the clarity and comprehensiveness of the 
information presented; the details given on the economic analysis, the alternatives being assessed and the context in which the technology would be applied. 
a
 NICE: National Institute for Health and Clinical Excellence 
b
 CEBM: Oxford Centre for Evidence Based Medicine 
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Table 2.  Description of the ICER results. 
 
Total cost per LYG cases 124 
Dominant cases 4 
Non dominant cost per LYG cases (n=120) 
Mean cost 49,529€ 
Standard deviation 183,080 
Median  11,490€ 
Minimum 85€ 
Maximum 1,844,481€ 
Robust mean 
M-estimator (Huber) 12,515€ 
 
 
Figure 1. Selection process 
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Figure 2. Annual distribution of the studies included 
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Figure 3. Year of study and cost per LYG results. 
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Figure 4. Study of cost per LYG and cost per QALY gained. 
 
Cost effectiveness threshold (ln)= 10.31€ (equal to 30,000€/QALY gained) 
The first and third quadrant show studies where cost per LYG and cost per QALY show the same 
(positive or negative) conclusion. Quadrant two shows studies where analysis by cost per QALY was 
not effective but cost per LYG was. Quadrant four shows studies where analysis by cost per LYG was 
not effective but cost per QALY was. 
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RESPONSE TO REVIEWERS COMMENTS 
 
Ref.: Ms. No. EJHE-D-10-00140 
 
The European Journal of Health Economics 
 
Dear Mr. Pérez Alcántara, 
 
Reviewers have now commented on your paper. You will see that they are advising that you revise your 
manuscript. If you are prepared to undertake the work required, I would be pleased to reconsider my 
decision. 
 
The reviewers' comments can be found at the end of this email or can be accessed by following the 
provided 
link. 
 
If you decide to revise the work, please submit a list of changes or a rebuttal against each point which is 
being raised when you submit the revised manuscript. 
 
Your revision is due by 02-03-2011. 
 
To submit a revision, go to http://ejhe.edmgr.com/ and log in as an Author. You will see a menu item call 
Submission Needing Revision. You will find your submission record there. 
 
Yours sincerely 
Wolfgang Greiner 
Managing Editor (Editorial Office) 
The European Journal of Health Economics 
 
Reviewers' comments: 
 
Reviewer #1: 
 
The manuscript EJHE-D-10-00140 is an interesting contribution to an important methodologic discussion, 
i.e. outcome measurement within the framework of health economic studies by means of life years gained 
(LYG) and cost per quality adjusted life year (QALY). The authors conducted a systematic review which 
aims at assessing the methodological quality of the increasing number of health economic evaluations in 
Spain and at investigating the relationship between the cost per LYG results and the cost per QALY. An 
additional analysis focuses on the question whether the recommended cost per LYG threshold published 
in Spain in 2002 has had an impact on afterwards published health economic evaluations. 
 
In the discussion section (p. 6, line 37f) the authors state that "the number and quality of published 
Spanish health economic evaluations seems to improve as years go by". In order to support this 
statement, quality criteria are pointed out in the same paragraph. The authors argue that "in past reviews" 
certain standards or quality criteria were not sufficiently met. This finding should be described in greater 
detail in the results section. Is there a break-even point, for instance a specific publication date of a study 
or a review, which marks the onset of the quality gain in health economic assessments in Spain? Or is it a 
continuous process of quality improvement? This point should be described more precisely. 
 
RESPONSE:  
 
We now state in the section ICER analysis: 
 
“However, a review by Sacristán et al. in 2002 found that most economic evaluations that recommended 
the adoption of a certain health intervention were based on ICE lower than 30,000 € per LYG [12]. This 
commonly-used threshold has been extended to cost per QALY and strengthened by the opinion of expert 
Spanish health economists [13].” Page 4 line 16 
 
In the Results section we now state:  
“Compared to previous systematic Spanish reviews [1,4], some methodological aspects seem to have 
improved. First, 82% of studies reviewed stated the perspective of the evaluation, compared to 28 and 
43%, respectively, in previous reviews [1,4]. Second, the incremental cost and LYG differences are shown 
together with incremental ratios in 84% of studies. Third, 97% of studies conducted some form of 
sensitivity analysis, an essential requirement for any good economic evaluation, compared with only 30-
68% [1,4] of past reviews. And fourth, although only 47% of studies stated the source of financing, this is 
greater than the 29% found in past reviews [4].” Page 7, line 21 
Authors' Response to Reviewers' Comments
Click here to download Authors' Response to Reviewers' Comments: Response_to_Reviewers_Manuscript_EurJHealthEcon_SpanishReview.doc
And:  
“As previously stated, a review published in 2002 found that most studies considered technologies with an 
incremental cost-effectiveness ratio below 30,000€ as efficient [12]. Our review showed that, since 2003, 
this unofficial threshold has been explicitly used as a reference by 66% of studies included.”  Page 9, line 
10 
 
In the Discussion section we now state:  
 
“Analysis of the methodological quality of the studies published since 2003, showed that 86% (30 of 35) 
were rated as (code++ or code +), showing the possible influence of previously published reviews in 2002 
[1,12] that may have led to greater methodological rigor. Moreover, it should be expected that the recent 
publication of Spanish recommendations on the economic evaluation of health technologies [11] will 
reinforce this trend in the future.” Page 11, line 6. 
 
END RESPONSE 
 
Another main critique is the following: At first sight, the significant correlation between cost per LYG and 
cost per QALY seems to be self-evident. Though, this correlation may vary across different types of 
diseases. The authors, being aware of this aspect, give examples for such as cancer and chronic illness 
(p. 7, line 46ff). Nevertheless, it is doubtful whether the statistical approach of this study is suitable for 
differentiating between the various illness conditions. The predominating impression after having read the 
paper is that the analyses equalize these differences rather than accentuating them. 
 
RESPONSE: 
We agree with the reviewer. We have added some points in the Discussion on this issue, and now 
conclude that:  
 
“Therefore, larger studies where the primary objective is to analyse the relationship between ICE 
thresholds and types of diseases would be necessary. In the present study, only 9 out of 58 results, 
corresponding to 4 studies, showed this discrepancy, which is not sufficient to reach any conclusions.” 
Page 13, line 25. 
 
END RESPONSE. 
 
Reviewer #2: 
 
Dear Editor/Dear Authors 
The Manuscript Number EJHE-D-10-00140 "The use of cost per life year as cost Effectiveness Gained 
measure result in Spain. A recent publications review" is an interesting exercise in two complementary 
dimensions: first, it can provide guidance on the threshold of acceptability implicitly used in Spanish 
economic evaluation of health interventions, and second, it can provide answers to whether the Spanish 
authors have accepted the threshold discussed by Sacristán et al in 2002. 
 
In my opinion, the authors commit two conceptual errors that influence the development of the manuscript. 
 
First, Sacristán et al. (2002) did not suggest or advocate that the threshold of acceptability (incremental 
cost per additional life year gained) should be set at ? 30,000 / LYG. Sacristán et al., reviewed the Spanish 
papers on economic evaluation of health care interventions published from 1990 to 2000 and analyzed the 
recommendations of the authors of these works on what is supposed to be worth the incremental cost 
effectiveness ratio efficiently. Therefore, a part of the work of the authors of the manuscript EJHE-D-10-
00140 had already been made by Sacristán et al. (2002). 
 
Secondly, it is wrong to cite that "Later threshold cost per QALY extended to by the Spanish Health 
Economics Association [13] ...." The threshold of 30,000 ?/LYG has been never adopted or recognized by 
the Spanish Health Economics Association in the debate on the need for greater use of economic 
evaluation studies in healthcare decision making (http://www.aes.es/Publicaciones/AESEE2.pdf). The 
reference 13 is only the opinion of a member of the Spanish Health Economics Association issued 
individually, not on behalf of the Spanish Health Economics Association. 
 
Therefore, my recommendation is that the manuscript EJHE-D-10-00140 was accepted for publication on 
condition that (a) the authors should carry out major changes in the manuscript and (b) the authors should 
focus their aim to respond if the threshold discussed in the work of Sacristán et al (2002) of ? 30,000 / LYG 
has been adopted as a reference in Spanish papers published in later years (from 2003 until now) or not. 
 
 
RESPONSE: 
 
We agree with the reviewer that no threshold was suggested either in the paper by Sacristan nor in any 
statement by the Spanish HEA and have revised the manuscript to emphasize this. We also include new 
material that addresses the question of whether the threshold suggested by Sacristán el al. have been 
adopted or has influenced Spanish papers published subsequently. 
 
END RESPONSE. 
 
 
More specifically: 
 
1) The review of economic evaluation studies carried out between 1990 and 2000 was yet conducted by 
Sacristán et al. (2002). Authors are encouraged to focus their review in the period following the publication 
of the work of Sacristán et al., ie the period 2003-2009. The opposite is repeat work already done and 
published. 
 
RESPONSE: 
 
We agree with the reviewer that, to some extent, we have „repeated‟ the review by Sacristán et al (2002), 
since we cover the period already analyzed in that paper. However, we believe that considering all 
economic evaluations (including those published before 2002) enabled us to better analyze the evolution 
of some aspects, such as the methodology quality of the studies or the potential influence of certain key 
publications like that by Sacristán et al. (2002). It also provides a larger sample size that may help in some 
of the analyses carried out. 
 
END RESPONSE. 
 
2) It would be interesting to include studies using the QALY as an outcome, since in the Spanish debate 
on the desirable value of the threshold, the figure of 30,000 euros has been used as a reference of a good 
value for a QALYs (eg reference 13). 
 
RESPONSE: 
 
A companion study using QALYs has already been carried out by Rodriguez-Barrios et al (2011, in press), 
the first author of the present study. Since C/LYG is also a commonly used C/E ratio, in this paper we 
wanted to focus on studies using C/LYG and introduce the comparison between this and C/QALY when 
both ratios where available (Rodriguez JM, Paz S, Lizan L, Gonzalez P. The use of Quality Adjusted Life 
Years (QALYs) in the economic evaluation of health technologies in Spain: a review of the 1990-2009 
literature. Value in Health 2011 Volume 14 Issue 4.) 
 
In the Discussion section we now state: 
 
“One limitation of this study is the narrow focus on methodologies using cost per LYG as a result. 
However, we believe that a detailed examination of this particular topic was desirable, since a similar 
review focused on the results of studies using cost per QALY has been published elsewhere [5].” Page 11, 
line 13. 
 
END RESPONSE. 
 
3) The authors should be used as an element to consider whether in the studies reviewed made explicit 
references to the article of Sacristán et al. (indicating that the authors knew the threshold discussed) and if 
the authors explicitly compare their results with the threshold discussed by Sacristán et al. (2002). Finally, 
another item to discuss would be whether the authors' recommendations were based on a comparison of 
the results of their studies with the threshold of ?30,000 per LYG or ?30,000 per QALY. In most of the 
studies cited so it is. And this is a strong argument in favour of the endogenization of the threshold of 
30,000 euros in the Spanish framework of the economic evaluation of health care technologies, contrary to 
what is suggested as a main conclusion of the manuscript. 
 
RESPONSE:  
 
In the Results section we now state: 
“As previously stated, a review published in 2002 found that most studies considered technologies with an 
incremental cost-effectiveness ratio below 30,000€ as efficient [12]. Our review showed that, since 2003, 
this unofficial threshold has been explicitly used as a reference by 66% of studies included.” Page 9, line 
10. 
 
In the Discussion section we now state: 
 
“Analysis of the methodological quality of the studies published since 2003, showed that 86% (30 of 35) 
were rated as (code++ or code +), showing the possible influence of previously published reviews in 2002 
[1,12] that may have led to greater methodological rigor. Moreover, it should be expected that the recent 
publication of Spanish recommendations on the economic evaluation of health technologies [11] will 
reinforce this trend in the future.”  Page 11, line 6 
And 
“Different thresholds have been stated in Spanish publications (ranging from 30,000€ to 50,000€/QALY) 
[12,21,22], but a recommendation of 30,000€/QALY gained is commonly considered as cost effective for 
most authors after the review by Sacristán et al. in 2002[12].” Page 12, line 10. 
 
END RESPONSE. 
 
4) It would be necessary to include control variables in the analysis or perform sensitivity analysis: Is it 
feasible to compare the results and findings of studies where the source of funding is private or where one 
or several authors works at private companies to the results and conclusions of studies where the source 
of funding is public or where the authors works at public organizations? Is it possible to compare the 
results and conclusions of the papers published in journals indexed in the Journal of Citation Report with 
those who are not? 
 
RESPONSE: 
 
We now state in the Results section: 
“Analysis of the cost per LYG of all studies reviewed according to the source of funding showed that robust 
mean results were quite similar (11,539€ for privately-funded studies, 18,855€ for publicly-funded studies 
and 13,069€ for studies without the source of funding stated). However, this comparison is biased due to 
the small number (3) of  publicly-funded studies.” Page 9, line 4.  
We were not able to compare studies appearing in indexed and non-indexed journals because only 19 of 
the 124 cost per LYG results were from studies published in non-indexed journals. 
 
END RESPONSE. 
 
5) Similarly, the authors should discuss the potential existence of publication bias in the field of economic 
evaluation when the cost-effectiveness ratio found is very high. The manuscript would benefit from a 
thorough discussion on this topic. 
 
RESPONSE: 
 
We now state in the Discussion section: 
 
“We found no clear influence of the commonly-used cost per LYG threshold of 30,000€ in studies 
published after the article by Sacristán et al (2002). However, an increase in the number of studies with 
cost per LYG results close to, but below, the 30,000€ threshold was found, which might indicate a certain 
temporary publication bias caused by the implicit acceptance of a threshold of efficiency, although more 
information would be needed to reach definitive conclusions.” Page 12, line 14. 
 
END RESPONSE. 
 
Minor comments: 
 
Authors should review the manuscript and correct some typos. 
 
RESPONSE: 
 
The manuscript has been revised by an English native medical translator. 
 
END RESPONSE. 
 
I would like to stress that if the manuscript is reviewed according to these suggestions, the work will be of 
great interest not only for Spanish readers, as he delves into a very important issue for European health 
policy makers as the endogenization of explicit or implicit thresholds of acceptability in the field economic 
evaluation is. 
 
I hope these comments are useful to the Editor and Authors 
 
Yours sincerely 
